Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
Menu

Contact Us
If you have any questions or feedback please contact us.

David M Woods

TitleAsst Professor
InstitutionUniversity of Colorado Denver - Anschutz Medical Campus
DepartmentSOM-MED

    Collapse Research 
    Collapse research activities and funding
    R00CA230201     (WOODS, DAVID MICHAEL)Sep 1, 2020 - May 31, 2023
    NIH
    Elucidating the Contextual Roles of IL-10 in Patient Response to Cancer Immunotherapy
    Role: Principal Investigator
    K99CA230201     (WOODS, DAVID MICHAEL)Aug 1, 2018 - Jul 31, 2020
    NIH
    Elucidating the Contextual Roles of IL-10 in Patient Response to Cancer Immunotherapy
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Khushalani NI, Vassallo M, Goldberg JD, Eroglu Z, Kim Y, Cao B, Ferguson R, Monson KR, Kirchhoff T, Amato CM, Burke P, Strange A, Monk E, Gibney GT, Kudchadkar R, Markowitz J, Brohl AS, Pavlick A, Richards A, Woods DM, Weber J. Phase II clinical and immune correlate study of adjuvant nivolumab plus ipilimumab for high-risk resected melanoma. J Immunother Cancer. 2022 11; 10(11). PMID: 36450385.
      View in: PubMed
    2. Woods D, Koerner J, Strage K, Chu X, Simon V, Hadeed M, Heare A, Parry JA, Mauffrey C. Defining Sacral Dysmorphism: What Size Corridor Precludes Transsacral Screw Placement. J Orthop Trauma. 2022 10 01; 36(10):498-502. PMID: 35452049.
      View in: PubMed
    3. Burke PEP, Strange A, Monk E, Thompson B, Amato CM, Woods DM. PhenoComb: a discovery tool to assess complex phenotypes in high-dimensional single-cell datasets. Bioinform Adv. 2022; 2(1):vbac052. PMID: 36699375.
      View in: PubMed
    4. Weber JS, Levinson BA, Laino AS, Pavlick AC, Woods DM. Clinical and immune correlate results from a phase 1b study of the histone deacetylase inhibitor mocetinostat with ipilimumab and nivolumab in unresectable stage III/IV melanoma. Melanoma Res. 2022 10 01; 32(5):324-333. PMID: 35678233.
      View in: PubMed
    5. Woods DM, Laino AS, Winters A, Alexandre J, Freeman D, Rao V, Adavani SS, Weber JS, Chattopadhyay PK. Nivolumab and ipilimumab are associated with distinct immune landscape changes and response-associated immunophenotypes. JCI Insight. 2020 06 04; 5(11). PMID: 32369447.
      View in: PubMed
    6. Yoshida T, Ichikawa J, Giuroiu I, Laino AS, Hao Y, Krogsgaard M, Vassallo M, Woods DM, Stephen Hodi F, Weber J. C reactive protein impairs adaptive immunity in immune cells of patients with melanoma. J Immunother Cancer. 2020 04; 8(1). PMID: 32303612.
      View in: PubMed
    7. Laino AS, Betts BC, Veerapathran A, Dolgalev I, Sarnaik A, Quayle SN, Jones SS, Weber JS, Woods DM. HDAC6 selective inhibition of melanoma patient T-cells augments anti-tumor characteristics. J Immunother Cancer. 2019 02 06; 7(1):33. PMID: 30728070.
      View in: PubMed
    8. Chattopadhyay PK, Winters AF, Lomas WE, Laino AS, Woods DM. High-Parameter Single-Cell Analysis. Annu Rev Anal Chem (Palo Alto Calif). 2019 06 12; 12(1):411-430. PMID: 30699035.
      View in: PubMed
    9. Yusko E, Vignali M, Wilson RK, Mardis ER, Hodi FS, Horak C, Chang H, Woods DM, Robins H, Weber J. Association of Tumor Microenvironment T-cell Repertoire and Mutational Load with Clinical Outcome after Sequential Checkpoint Blockade in Melanoma. Cancer Immunol Res. 2019 03; 7(3):458-465. PMID: 30635271.
      View in: PubMed
    10. Woods DM, Ramakrishnan R, Laino AS, Berglund A, Walton K, Betts BC, Weber JS. Decreased Suppression and Increased Phosphorylated STAT3 in Regulatory T Cells are Associated with Benefit from Adjuvant PD-1 Blockade in Resected Metastatic Melanoma. Clin Cancer Res. 2018 12 15; 24(24):6236-6247. PMID: 30131384.
      View in: PubMed
    11. Briere D, Sudhakar N, Woods DM, Hallin J, Engstrom LD, Aranda R, Chiang H, Sodr? AL, Olson P, Weber JS, Christensen JG. The class I/IV HDAC inhibitor mocetinostat increases tumor antigen presentation, decreases immune suppressive cell types and augments checkpoint inhibitor therapy. Cancer Immunol Immunother. 2018 03; 67(3):381-392. PMID: 29124315.
      View in: PubMed
    12. Jacquelot N, Roberti MP, Enot DP, Rusakiewicz S, Tern?s N, Jegou S, Woods DM, Sodr? AL, Hansen M, Meirow Y, Sade-Feldman M, Burra A, Kwek SS, Flament C, Messaoudene M, Duong CPM, Chen L, Kwon BS, Anderson AC, Kuchroo VK, Weide B, Aubin F, Borg C, Dalle S, Beatrix O, Ayyoub M, Balme B, Tomasic G, Di Giacomo AM, Maio M, Schadendorf D, Melero I, Dr?no B, Khammari A, Dummer R, Levesque M, Koguchi Y, Fong L, Lotem M, Baniyash M, Schmidt H, Svane IM, Kroemer G, Marabelle A, Michiels S, Cavalcanti A, Smyth MJ, Weber JS, Eggermont AM, Zitvogel L. Predictors of responses to immune checkpoint blockade in advanced melanoma. Nat Commun. 2017 09 19; 8(1):592. PMID: 28928380.
      View in: PubMed
    13. Woods DM, Woan KV, Cheng F, Sodr? AL, Wang D, Wu Y, Wang Z, Chen J, Powers J, Pinilla-Ibarz J, Yu Y, Zhang Y, Wu X, Zheng X, Weber J, Hancock WW, Seto E, Villagra A, Yu XZ, Sotomayor EM. T cells lacking HDAC11 have increased effector functions and mediate enhanced alloreactivity in a murine model. Blood. 2017 07 13; 130(2):146-155. PMID: 28550044.
      View in: PubMed
    14. Woods DM, Sodr? AL, Villagra A, Sarnaik A, Sotomayor EM, Weber J. HDAC Inhibition Upregulates PD-1 Ligands in Melanoma and Augments Immunotherapy with PD-1 Blockade. Cancer Immunol Res. 2015 Dec; 3(12):1375-85. PMID: 26297712.
      View in: PubMed
    15. Woan KV, Lienlaf M, Perez-Villaroel P, Lee C, Cheng F, Knox T, Woods DM, Barrios K, Powers J, Sahakian E, Wang HW, Canales J, Marante D, Smalley KSM, Bergman J, Seto E, Kozikowski A, Pinilla-Ibarz J, Sarnaik A, Celis E, Weber J, Sotomayor EM, Villagra A. Targeting histone deacetylase 6 mediates a dual anti-melanoma effect: Enhanced antitumor immunity and impaired cell proliferation. Mol Oncol. 2015 Aug; 9(7):1447-1457. PMID: 25957812.
      View in: PubMed
    16. Sahakian E, Powers JJ, Chen J, Deng SL, Cheng F, Distler A, Woods DM, Rock-Klotz J, Sodre AL, Youn JI, Woan KV, Villagra A, Gabrilovich D, Sotomayor EM, Pinilla-Ibarz J. Histone deacetylase 11: A novel epigenetic regulator of myeloid derived suppressor cell expansion and function. Mol Immunol. 2015 Feb; 63(2):579-85. PMID: 25155994.
      View in: PubMed
    17. Woods DM, Woan K, Cheng F, Wang H, Perez-Villarroel P, Lee C, Lienlaf M, Atadja P, Seto E, Weber J, Sotomayor EM, Villagra A. The antimelanoma activity of the histone deacetylase inhibitor panobinostat (LBH589) is mediated by direct tumor cytotoxicity and increased tumor immunogenicity. Melanoma Res. 2013 Oct; 23(5):341-8. PMID: 23963286.
      View in: PubMed
    Woods's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    See all (118) concept(s)
    _
    Co-Authors Expand Description
    See all (2) people
    _
    Similar People Expand Description
    See all (60) people
    _
    Same Department Expand Description
    Search Department

    Copyright © 2023 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)